Expected rebound ahead of the 25 June FDA action date for Plazomicin for the Treatment of Complicated Urinary Tract Infections and Bloodstream Infections
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
